Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 173.52
- Piotroski Score 4.00
- Grade Buy
- Symbol (VKTX)
- Company Viking Therapeutics, Inc.
- Price $64.81
- Changes Percentage (-3.41%)
- Change -$2.29
- Day Low $64.11
- Day High $67.06
- Year High $99.41
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/22/2024
- Fiscal Year End N/A
- Average Stock Price Target $110.50
- High Stock Price Target $138.00
- Low Stock Price Target $15.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.92
- Trailing P/E Ratio -60.86
- Forward P/E Ratio -60.86
- P/E Growth -60.86
- Net Income $-85,895,000
Income Statement
Quarterly
Annual
Latest News of VKTX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Why you Should Buy the 200-day Dip in ARM, MSTR, VKTX
Amateur investors often complicate their strategies with excessive indicators. Simplifying by focusing on key tools like the 200-day moving average can aid in trend identification, risk management, an...
By Yahoo! Finance | 1 week ago -
Viking Therapeutics, Inc. (VKTX): One of Oppenheimer's Top Stock Picks For the Next 12 Months
Oppenheimer's top stock picks for the next 12 months include Viking Therapeutics, Inc. (NASDAQ:VKTX), a biotech company with promising drug candidates for liver diseases and weight loss. Despite its p...
By Yahoo! Finance | 2 weeks ago -
Director J Singleton Sells 5,700 Shares of Viking Therapeutics Inc (VKTX)
Viking Therapeutics Inc is a biopharmaceutical company focusing on metabolic disorders. An insider sold shares valued at $397,404, part of a trend with no insider buys in a year. Investors can track i...
By Yahoo! Finance | 3 weeks ago
